BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Ferrero A, Schulick RD, Choti MA, Mentha G, Strub J, Bauer TW, Adams RB, Aldrighetti L, Capussotti L, Pawlik TM. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129-3136. [PMID: 20585879 DOI: 10.1245/s10434-010-1154-5] [Cited by in Crossref: 266] [Cited by in F6Publishing: 218] [Article Influence: 24.2] [Reference Citation Analysis]
Number Citing Articles
1 Bergsland EK. The Evolving Landscape of Neuroendocrine Tumors. Seminars in Oncology 2013;40:4-22. [DOI: 10.1053/j.seminoncol.2012.11.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
2 Farley HA, Pommier RF. Treatment of Neuroendocrine Liver Metastases. Surgical Oncology Clinics of North America 2016;25:217-25. [DOI: 10.1016/j.soc.2015.08.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
3 Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR. Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol 2014;21:2971-80. [PMID: 24752611 DOI: 10.1245/s10434-014-3728-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
4 杜顺达, 王孜, 毛一雷. 神经内分泌肿瘤肝转移治疗的进展. 世界华人消化杂志 2013; 21(36): 4069-4074 [DOI: 10.11569/wcjd.v21.i36.4069] [Reference Citation Analysis]
5 Argentiero A, Calabrese A, Sciacovelli AM, Delcuratolo S, Solimando AG, Brunetti O. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. Can J Gastroenterol Hepatol 2020;2020:8679751. [PMID: 33102398 DOI: 10.1155/2020/8679751] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012;2012:819193. [PMID: 22518323 DOI: 10.1155/2012/819193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
7 Abreu P, Ferreira R, Bussyguin DS, DaCás E, Venkatasamy VV, Tomasich FDS, Szutan LA. Liver resections for metastasis: surgical outcomes of a single center academic institution. BMC Surg 2020;20:254. [PMID: 33109145 DOI: 10.1186/s12893-020-00920-7] [Reference Citation Analysis]
8 Pasqual EM, Bertozzi S, Londero AP, Bacchetti S, Lorenzin D, Pasqualucci A, Moccheggiani F, Federici A, Vivaverlli M, Risaliti A. Long term results of hepatic resection or orthotopic liver transplantation in patients with liver metastases from gastrointestinal neuroendocrine tumors. Oncol Lett 2016;12:3563-70. [PMID: 27900037 DOI: 10.3892/ol.2016.5045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
9 Tan MC, Jarnagin WR. Surgical management of non-colorectal hepatic metastasis: Non-Colorectal Metastatectomy. J Surg Oncol 2014;109:8-13. [DOI: 10.1002/jso.23462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
10 Vaghaiwalla T, Keutgen XM. Surgical Management of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:243-52. [PMID: 32151358 DOI: 10.1016/j.soc.2019.11.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 Spolverato G, Bagante F, Wagner D, Buettner S, Gupta R, Kim Y, Maqsood H, Pawlik TM. Quality of life after treatment of neuroendocrine liver metastasis. J Surg Res. 2015;198:155-164. [PMID: 26095419 DOI: 10.1016/j.jss.2015.05.048] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
12 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
13 Pourmand K, Itzkowitz SH. Small Bowel Neoplasms and Polyps. Curr Gastroenterol Rep 2016;18:23. [PMID: 27086004 DOI: 10.1007/s11894-016-0497-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
14 Orcutt ST, Abuodeh Y, Naghavi A, Frakes J, Hoffe S, Kis B, Anaya DA. Kinetic analysis of contralateral liver hypertrophy after radioembolization of primary and metastatic liver tumors. Surgery 2018;163:1020-7. [PMID: 29325784 DOI: 10.1016/j.surg.2017.11.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Xiang JX, Zhang XF, Beal EW, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter? Ann Surg Oncol. 2018;25:3928-3935. [PMID: 30218247 DOI: 10.1245/s10434-018-6751-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
16 Hanazaki K, Sakurai A, Munekage M, Ichikawa K, Namikawa T, Okabayashi T, Imamura M. Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg Today. 2013;43:229-236. [PMID: 23076685 DOI: 10.1007/s00595-012-0376-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
17 Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R;  Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8-21. [PMID: 24384494 DOI: 10.1016/s1470-2045(13)70362-0] [Cited by in Crossref: 256] [Cited by in F6Publishing: 109] [Article Influence: 36.6] [Reference Citation Analysis]
18 Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D, Lee B, Singh G. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. Ann Surg 2019;270:1131-7. [PMID: 29746336 DOI: 10.1097/SLA.0000000000002809] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
19 Spolverato G, Vitale A, Ejaz A, Kim Y, Cosgrove D, Schlacter T, Geschwind J, Pawlik TM. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery 2015;158:339-48. [DOI: 10.1016/j.surg.2015.03.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
20 Omichi K, Mizuno T, Okuno M, Tzeng CD, Conrad C, Chun YS, Aloia TA, Vauthey JN. Long term outcome after resection of liver metastases from squamous cell carcinoma. Eur J Surg Oncol 2017;43:2129-34. [PMID: 28958732 DOI: 10.1016/j.ejso.2017.09.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Taner T, Atwell TD, Zhang L, Oberg TN, Harmsen WS, Slettedahl SW, Kendrick ML, Nagorney DM, Que FG. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB (Oxford). 2013;15:190-195. [PMID: 23374359 DOI: 10.1111/j.1477-2574.2012.00528.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
22 Kang XN, Zhang XY, Bai J, Wang ZY, Yin WJ, Li L. Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm. World J Gastrointest Oncol 2019; 11(5): 436-448 [PMID: 31139313 DOI: 10.4251/wjgo.v11.i5.436] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
24 Rogowski P, von Bestenbostel R, Walter F, Straub K, Nierer L, Kurz C, Landry G, Reiner M, Auernhammer CJ, Belka C, Niyazi M, Corradini S. Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors. Cancers (Basel) 2021;13:1523. [PMID: 33810244 DOI: 10.3390/cancers13071523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
25 Bergsland EK, Woltering EA, Rindi G, O’dorisio TM, Schilsky RL, Liu EH, Kim MK, Nakakura EK, Reidy-lagunes DL, Strosberg JR, Tang LH, Vinik AI, Wang Y, Asare EA, Brierley JD, Bushnell DL, Jensen RT, Pommier RF, Wolin EM, Wong RK, Klimstra DS. Neuroendocrine Tumors of the Pancreas. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. Cham: Springer International Publishing; 2017. pp. 407-19. [DOI: 10.1007/978-3-319-40618-3_34] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
26 Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol 2017;2017:6424812. [PMID: 28593056 DOI: 10.1155/2017/6424812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Groeschl RT, Wong RK, Quebbeman EJ, Tsai S, Turaga KK, Pappas SG, Christians KK, Hohenwalter EJ, Tutton SM, Rilling WS, Gamblin TC. Recurrence after microwave ablation of liver malignancies: a single institution experience. HPB (Oxford) 2013;15:365-71. [PMID: 23458599 DOI: 10.1111/j.1477-2574.2012.00585.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
28 Bösch F, Werner J, Angele MK, Guba MO. [Oligometastases of neuroendocrine tumors-extent of surgery]. Chirurg 2018;89:516-22. [PMID: 29876615 DOI: 10.1007/s00104-018-0644-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Gut P. Liver metastases in gastroenteropancreatic neuroendocrine tumours - treatment methods. Prz Gastroenterol 2020;15:207-14. [PMID: 33005265 DOI: 10.5114/pg.2020.91501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Asban A, Patel AJ, Reddy S, Wang T, Balentine CJ, Chen H. Cancer of the Endocrine System. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1074-1107.e11. [DOI: 10.1016/b978-0-323-47674-4.00068-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sherman SK, Howe JR. Translational research in endocrine surgery. Surg Oncol Clin N Am 2013;22:857-84. [PMID: 24012403 DOI: 10.1016/j.soc.2013.06.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
32 Aoki T, Kubota K, Kiritani S, Arita J, Morizane C, Masui T, Kudo A, Komoto I, Hatano E, Ito T, Osamura RY, Unno M, Uemoto S, Kokudo N; Japanese Neuroendocrine Tumor Society (JNETS). Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS). J Hepatobiliary Pancreat Sci 2021;28:489-97. [PMID: 33792204 DOI: 10.1002/jhbp.956] [Reference Citation Analysis]
33 Lorenzen AW, O'Dorisio TM, Howe JR. Neuroendocrine tumors arising in Meckel's diverticula: frequency of advanced disease warrants aggressive management. J Gastrointest Surg 2013;17:1084-91. [PMID: 23558715 DOI: 10.1007/s11605-013-2191-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
34 Ejaz A, Reames BN, Maithel S, Poultsides GA, Bauer TW, Fields RC, Weiss MJ, Marques HP, Aldrighetti L, Pawlik TM. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. HPB (Oxford). 2018;20:277-284. [PMID: 28964630 DOI: 10.1016/j.hpb.2017.08.039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
35 Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim M, Warren RS, Bergsland EK, Nakakura EK. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. J Surg Oncol 2019;121:330-6. [DOI: 10.1002/jso.25811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Concors SJ, Sinnamon AJ, Ecker BL, Metz DC, Vollmer CM, Fraker DL, Roses RE. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level. HPB (Oxford) 2020;22:83-90. [PMID: 31239188 DOI: 10.1016/j.hpb.2019.05.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Armutlu A, Saeed O, Saxena R. Metastatic Liver Tumors in Surgical Pathology: Impact of Contemporary Diagnostic and Therapeutic Paradigms in a Tertiary Care Center. Int J Surg Pathol 2021;:10668969211022708. [PMID: 34125627 DOI: 10.1177/10668969211022708] [Reference Citation Analysis]
38 Ejaz A, Reames BN, Maithel S, Poultsides GA, Bauer TW, Fields RC, Weiss M, Marques HP, Aldrighetti L, Pawlik TM. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis. J Surg Oncol 2017;116:841-7. [PMID: 28650564 DOI: 10.1002/jso.24727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
39 Castillo JG, Milla F, Adams DH. Surgical Management of Carcinoid Heart Valve Disease. Seminars in Thoracic and Cardiovascular Surgery 2012;24:254-60. [DOI: 10.1053/j.semtcvs.2012.11.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
40 Krausch M, Raffel A, Anlauf M, Schott M, Lehwald N, Krieg A, Topp SA, Cupisti K, Knoefel WT. “Cherry Picking”, a Multiple Non-anatomic Liver Resection Technique, as a Promising Option for Diffuse Liver Metastases in Patients with Neuroendocrine Tumours. World J Surg 2014;38:392-401. [DOI: 10.1007/s00268-013-2267-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
41 Johnston ME 2nd, Carter MM, Wilson GC, Ahmad SA, Patel SH. Surgical management of primary pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:578-89. [PMID: 32655937 DOI: 10.21037/jgo.2019.12.09] [Reference Citation Analysis]
42 Sahara K, Merath K, Tsilimigras DI, Hyer JM, Guglielmi A, Aldrighetti L, Weiss M, Fields RC, Poultsides GA, Maithel SK, Endo I, Pawlik TM, other members of the U.s. Neuroendo. Conditional disease‐free survival after curative‐intent liver resection for neuroendocrine liver metastasis. J Surg Oncol 2019;120:1087-95. [DOI: 10.1002/jso.25713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
43 Bacchetti S, Bertozzi S, Londero AP, Uzzau A, Pasqual EM. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040. [PMID: 23509630 DOI: 10.1155/2013/235040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
44 Tsilimigras DI, Xiang JX, Zhang XF, Pawlik TM. ASO Author Reflections: A Nomogram to Predict Recurrence after Curative-Intent Resection for Neuroendocrine Liver Metastasis. Ann Surg Oncol 2020;27:3727-8. [PMID: 32440717 DOI: 10.1245/s10434-020-08622-3] [Reference Citation Analysis]
45 Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel) 2019;11:E1395. [PMID: 31540509 DOI: 10.3390/cancers11091395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
46 Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N. Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. Ann Surg Oncol 2019;26:1385-93. [PMID: 30863939 DOI: 10.1245/s10434-019-07252-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
47 Chouliaras K, Newman NA, Shukla M, Swett KR, Levine EA, Sham J, Mann GN, Shen P. Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. J Surg Oncol 2018;118:416-21. [PMID: 30259518 DOI: 10.1002/jso.25146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
48 Kulik U, Lehner F, Bektas H, Klempnauer J. Liver Resection for Non-Colorectal Liver Metastases - Standards and Extended Indications. Viszeralmedizin 2015;31:394-8. [PMID: 26889142 DOI: 10.1159/000439419] [Reference Citation Analysis]
49 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
50 Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, Bassi C, Di Carlo V, Pederzoli P. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17:1621-1627. [PMID: 20162460 DOI: 10.1155/2012/782672] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
51 Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver Ablation: Best Practice. Radiol Clin North Am 2015;53:933-71. [PMID: 26321447 DOI: 10.1016/j.rcl.2015.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
52 Cai JS, Chen HY, Lu YF, Yu RS. A prognostic nomogram in patients with distant metastasis of pancreatic neuroendocrine tumors: a population-based study. Future Oncol 2020;16:4369-79. [PMID: 31802701 DOI: 10.2217/fon-2019-0545] [Reference Citation Analysis]
53 Orcutt ST, Artinyan A, Li LT, Silberfein EJ, Berger DH, Albo D, Anaya DA. Postoperative mortality and need for transitional care following liver resection for metastatic disease in elderly patients: a population-level analysis of 4026 patients. HPB (Oxford) 2012;14:863-70. [PMID: 23134189 DOI: 10.1111/j.1477-2574.2012.00577.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
54 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
55 Partelli S, Cirocchi R, Rancoita PM, Muffatti F, Andreasi V, Crippa S, Tamburrino D, Falconi M. A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. HPB 2018;20:197-203. [DOI: 10.1016/j.hpb.2017.10.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
56 Saxena A, Chua TC, Chu F, Al-Zahrani A, Morris DL. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. Am J Clin Oncol. 2012;35:439-445. [PMID: 21654315 DOI: 10.1097/coc.0b013e31821bc8dd] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
57 Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB;  UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6-32. [PMID: 22052063 DOI: 10.1136/gutjnl-2011-300831] [Cited by in Crossref: 353] [Cited by in F6Publishing: 280] [Article Influence: 35.3] [Reference Citation Analysis]
58 Perälä J, Klemola R, Kallio R, Li C, Vihriälä I, Salmela PI, Tervonen O, Sequeiros RB. MRI-guided laser ablation of neuroendocrine tumor hepatic metastases. Acta Radiol Short Rep 2014;3:2047981613499753. [PMID: 24778794 DOI: 10.1177/2047981613499753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
59 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
60 Du S, Ni J, Weng L, Ma F, Li S, Wang W, Sang X, Lu X, Zhong S, Mao Y. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors. Medicine (Baltimore) 2015;94:e1429. [PMID: 26313798 DOI: 10.1097/MD.0000000000001429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
61 Page AJ, Cosgrove D, Pawlik TM. Comparative effectiveness in hepatic malignancies. Cancer Treat Res 2015;164:195-219. [PMID: 25677025 DOI: 10.1007/978-3-319-12553-4_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
62 Wang SC, Fidelman N, Nakakura EK. Management of Well-Differentiated Gastrointestinal Neuroendocrine Tumors Metastatic to the Liver. Seminars in Oncology 2013;40:69-74. [DOI: 10.1053/j.seminoncol.2012.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
63 Chawla A, Williams RT, Sich N, Clancy T, Wang J, Ashley S, Pezzi C, Swanson R. Pancreaticoduodenectomy and metastasectomy for metastatic pancreatic neuroendocrine tumors: CHAWLA et al.. J Surg Oncol 2018;118:983-90. [DOI: 10.1002/jso.25219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
64 Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020;9:440-451. [PMID: 32832495 DOI: 10.21037/hbsn.2020.04.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Chakedis J, Beal EW, Lopez-aguiar AG, Poultsides G, Makris E, Rocha FG, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Marincola-smith P, Cho C, Beems M, Pawlik TM, Maithel SK, Schmidt CR, Dillhoff M. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. J Gastrointest Surg 2019;23:122-34. [DOI: 10.1007/s11605-018-3986-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
66 Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, Li Z, Reyes D, Cosgrove D, Pawlik TM, Diaz LA, Bhagat N, Eng J. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology. 2013;266:502-513. [PMID: 23192780 DOI: 10.1148/radiol.12120495] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
67 Clift AK, Frilling A. Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. World J Gastroenterol 2018; 24(20): 2152-2162 [PMID: 29853733 DOI: 10.3748/wjg.v24.i20.2152] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
68 Egger ME, Armstrong E, Martin RC 2nd, Scoggins CR, Philips P, Shah M, Konda B, Dillhoff M, Pawlik TM, Cloyd JM. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. J Am Coll Surg. 2020;230:363-370. [PMID: 32032719 DOI: 10.1016/j.jamcollsurg.2019.12.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
69 Bacchetti S, Pasqual EM, Bertozzi S, Londero AP, Risaliti A. Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. Gland Surg. 2014;3:243-251. [PMID: 25493256 DOI: 10.3978/j.issn.2227-684x.2014.02.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
70 Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology 2020;145:102835. [DOI: 10.1016/j.critrevonc.2019.102835] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
71 Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43:526-531. [PMID: 24658317 DOI: 10.1097/mpa.0000000000000065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
72 Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Ercolani G, Giuliante F, Ferrero A, Torzilli G, Grazi GL, Ratti F, Cucchetti A, De Rose AM, Russolillo N, Cimino M, Perri P, Cataldo I, Scarpa A, Guglielmi A, Iacono C. A Novel Nomogram to Predict the Prognosis of Patients Undergoing Liver Resection for Neuroendocrine Liver Metastasis: an Analysis of the Italian Neuroendocrine Liver Metastasis Database. J Gastrointest Surg 2017;21:41-8. [DOI: 10.1007/s11605-016-3228-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
73 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg 2015;19:2273-82. [DOI: 10.1007/s11605-015-2931-z] [Reference Citation Analysis]
74 Pasricha G, Padhi P, Daboul N, Monga DK. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review. Clin Ther 2017;39:2146-57. [PMID: 29173655 DOI: 10.1016/j.clinthera.2017.10.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
75 Bagante F, Spolverato G, Merath K, Postlewait LM, Poultsides GA, Mullen MG, Bauer TW, Fields RC, Lamelas J, Marques HP, Aldrighetti L, Tran T, Maithel SK, Pawlik TM. Neuroendocrine liver metastasis: The chance to be cured after liver surgery. J Surg Oncol 2017;115:687-95. [PMID: 28146608 DOI: 10.1002/jso.24563] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
76 Tamburrino D, Spoletini G, Partelli S, Muffatti F, Adamenko O, Crippa S, Falconi M. Surgical management of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2016;30:93-102. [PMID: 26971846 DOI: 10.1016/j.beem.2015.10.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
77 Chan KS, Low JK, Shelat VG. Associated liver partition and portal vein ligation for staged hepatectomy: a review. Transl Gastroenterol Hepatol 2020;5:37. [PMID: 32632388 DOI: 10.21037/tgh.2019.12.01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
78 Lee SY, Cheow PC, Teo JY, Ooi LL. Surgical treatment of neuroendocrine liver metastases. Int J Hepatol 2012;2012:146590. [PMID: 22319650 DOI: 10.1155/2012/146590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
79 Maxwell JE, O'Dorisio TM, Howe JR. Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2016;25:171-94. [PMID: 26610781 DOI: 10.1016/j.soc.2015.08.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
80 Alagusundaramoorthy SS, Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol 2014; 20(39): 14348-14358 [PMID: 25339822 DOI: 10.3748/wjg.v20.i39.14348] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
81 Clancy TE. Surgical Management of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016;30:103-18. [PMID: 26614371 DOI: 10.1016/j.hoc.2015.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
82 Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015;35:92-103. [PMID: 25993147 DOI: 10.14694/EdBook_AM.2015.35.92] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 5.2] [Reference Citation Analysis]
83 Kolbeck KJ, Farsad K. Catheter-based treatments for hepatic metastases from neuroendocrine tumors. AJR Am J Roentgenol. 2014;203:717-724. [PMID: 25247935 DOI: 10.2214/ajr.14.12983] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
84 Clarke NAR, Kanhere HA, Trochsler MI, Maddern GJ. Liver resection for non-colorectal non-neuroendocrine metastases. ANZ J Surg. 2018;88:E313-E317. [PMID: 27490345 DOI: 10.1111/ans.13700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
85 Zhang XF, Beal EW, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis. J Surg Oncol. 2018;117:171-181. [PMID: 28940257 DOI: 10.1002/jso.24832] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
86 Das S, Berlin J. Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. Surg Oncol Clin N Am 2021;30:189-204. [PMID: 33220805 DOI: 10.1016/j.soc.2020.08.008] [Reference Citation Analysis]
87 Gu P, Wu J, Newman E, Muggia F. Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin. Int J Hepatol 2012;2012:131659. [PMID: 22518318 DOI: 10.1155/2012/131659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
88 Sauvanet A. Gastroenteropancreatic neuroendocrine tumors: Role of surgery. Ann Endocrinol (Paris) 2019;80:175-81. [PMID: 31079831 DOI: 10.1016/j.ando.2019.04.009] [Reference Citation Analysis]
89 Spolverato G, Bagante F, Aldrighetti L, Poultsides G, Bauer TW, Field RC, Marques HP, Weiss M, Maithel SK, Pawlik TM. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surg 2017;21:2039-47. [PMID: 28744737 DOI: 10.1007/s11605-017-3491-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
90 Callahan AF, White M, Ituarte P, Gagandeep S, Woo Y, Fong Y, Melstrom L. Surgical Intervention in Gastric Carcinoid is Associated With Improved Survival in Local and Regional Disease. Am J Clin Oncol 2018;41:882-7. [PMID: 28763328 DOI: 10.1097/COC.0000000000000392] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
91 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Reference Citation Analysis]
92 Luley K, Gebauer J, Gebauer N, Tharun L, Buchmann I, Barkhausen J, von Bubnoff N, Lindner K, Keck T, Lehnert H, Schmid SM. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research]. Internist (Berl). 2020;61:875-890. [PMID: 32676723 DOI: 10.1007/s00108-020-00832-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Deutsch GB, Lee JH, Bilchik AJ. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma. J Am Coll Surg. 2015;221:26-36. [PMID: 26027502 DOI: 10.1016/j.jamcollsurg.2015.03.055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
94 Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, de Jong MC, Pawlik TM, Geller DA, Tsung A, Marsh JW, Clary BM, Curley SA, Gamblin TC. Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis. Journal of the American College of Surgeons 2012;214:769-77. [DOI: 10.1016/j.jamcollsurg.2011.12.048] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 9.7] [Reference Citation Analysis]
95 Tanno L, Mayo D, Mills S, Takhar A, Cave J, Nolan L, Stedman B, Sundram FX, Abu Hilal M, Connor H, Pearce N, Armstrong T. Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits. Pancreatology 2018;18:304-12. [PMID: 29433805 DOI: 10.1016/j.pan.2017.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
96 Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163:218-225. [PMID: 29103583 DOI: 10.1016/j.surg.2017.05.030] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
97 Wonn SM, Limbach KE, Pommier SJ, Ratzlaff AN, Leon EJ, McCully BH, Pommier RF. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors. Surgery 2021;169:168-74. [PMID: 32473829 DOI: 10.1016/j.surg.2020.03.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
99 Andreasi V, Muffatti F, Guarneri G, Falconi M, Partelli S. Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. Curr Treat Options Oncol. 2020;21:48. [PMID: 32350693 DOI: 10.1007/s11864-020-00736-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Foubert F, Salimon M, Dumars C, Regenet N, Girot P, Venara A, Senellart H, Heymann MF, Matysiak-Budnik T, Touchefeu Y. Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. J Gastrointest Oncol 2019;10:103-11. [PMID: 30788165 DOI: 10.21037/jgo.2018.09.13] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Park GK, Lee JH, Soriano E, Choi M, Bao K, Katagiri W, Kim DY, Paik JH, Yun SH, Frangioni JV, Clancy TE, Kashiwagi S, Henary M, Choi HS. Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors. iScience 2020;23:101006. [PMID: 32268281 DOI: 10.1016/j.isci.2020.101006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Frilling A, Clift AK, Braat AJ, Alsafi A, Wasan HS, Al-nahhas A, Thomas R, Drymousis P, Habib N, Tait PN. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB 2019;21:773-83. [DOI: 10.1016/j.hpb.2018.12.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
103 Cheung TT, Chok KS, Chan AC, Tsang S, Dai JW, Lang BH, Yau T, Chan SC, Poon RT, Fan ST, Lo CM. Long term survival analysis of hepatectomy for neuroendocrine tumour liver metastases. ScientificWorldJournal 2014;2014:524045. [PMID: 24526905 DOI: 10.1155/2014/524045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
104 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:223-41. [PMID: 32151357 DOI: 10.1016/j.soc.2019.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
105 Tomozawa Y, Jahangiri Y, Pathak P, Kolbeck KJ, Schenning RC, Kaufman JA, Farsad K. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases. Journal of Vascular and Interventional Radiology 2018;29:858-65. [DOI: 10.1016/j.jvir.2018.02.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
106 Takemura N, Saiura A. Role of surgical resection for non-colorectal non-neuroendocrine liver metastases. World J Hepatol 2017; 9(5): 242-251 [PMID: 28261381 DOI: 10.4254/wjh.v9.i5.242] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
107 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg 2015;19:2273-82. [DOI: 10.1007/s11605-015-2931-z] [Reference Citation Analysis]
108 Reddy SK, Barbas AS, Turley RS, Steel JL, Tsung A, Marsh JW, Geller DA, Clary BM. A standard definition of major hepatectomy: resection of four or more liver segments. HPB (Oxford) 2011;13:494-502. [PMID: 21689233 DOI: 10.1111/j.1477-2574.2011.00330.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 103] [Article Influence: 12.0] [Reference Citation Analysis]
109 Zhang S, Tong YX, Zhang XH, Zhang YJ, Xu XS, Xiao AT, Chao TF, Gong JP. A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms. J Cancer 2019;10:5944-54. [PMID: 31762804 DOI: 10.7150/jca.35785] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
110 Farley HA, Pommier RF. Surgical Treatment of Small Bowel Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016;30:49-61. [PMID: 26614368 DOI: 10.1016/j.hoc.2015.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
111 Pickens RC, Sulzer JK, Passeri MJ, Murphy K, Vrochides D, Martinie JB, Baker EH, Ocuin LM, McKillop IH, Iannitti DA. Operative Microwave Ablation for the Multimodal Treatment of Neuroendocrine Liver Metastases. J Laparoendosc Adv Surg Tech A 2021;31:917-25. [PMID: 33296283 DOI: 10.1089/lap.2020.0558] [Reference Citation Analysis]
112 Hori T, Takaori K, Uemoto S. Pancreatic neuroendocrine tumor accompanied with multiple liver metastases. World J Hepatol 2014; 6(8): 596-600 [PMID: 25232452 DOI: 10.4254/wjh.v6.i8.596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
113 Kose E, Kahramangil B, Aydin H, Donmez M, Takahashi H, Aucejo F, Siperstein A, Berber E. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience. Surg Endosc. 2020;34:249-256. [PMID: 30945061 DOI: 10.1007/s00464-019-06759-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
114 Modlin IM, Frilling A, Salem RR, Alaimo D, Drymousis P, Wasan HS, Callahan S, Faiz O, Weng L, Teixeira N, Bodei L, Drozdov I, Kidd M. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery 2016;159:336-47. [PMID: 26456125 DOI: 10.1016/j.surg.2015.06.056] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
115 Kaemmerer D, Prasad V, Daffner W, Haugvik SP, Senftleben S, Baum RP, Hommann M. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. Clin Nucl Med 2012;37:142-7. [PMID: 22228336 DOI: 10.1097/RLU.0b013e3182291de8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
116 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract. 2018;14: 471-482. [PMID: 30096273 DOI: 10.1200/jop.18.00135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
117 Saxena A, Chua TC, Zhao J, Morris DL. Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery. J Surg Oncol 2012;105:342-50. [PMID: 22006355 DOI: 10.1002/jso.22114] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
118 Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol 2017; 23(15): 2640-2650 [PMID: 28487601 DOI: 10.3748/wjg.v23.i15.2640] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
119 Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol. 2012;13:24-34. [PMID: 22198808 DOI: 10.1007/s11864-011-0172-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
120 Bergsland EK. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Semin Oncol 2013;40:1-3. [PMID: 23391108 DOI: 10.1053/j.seminoncol.2012.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
121 Fromer MW, Aloia TA, Gaughan JP, Atabek UM, Spitz FR. The utility of the MELD score in predicting mortality following liver resection for metastasis. Eur J Surg Oncol 2016;42:1568-75. [PMID: 27365199 DOI: 10.1016/j.ejso.2016.05.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
122 Frilling A, Clift AK. Surgical Approaches to the Management of Neuroendocrine Liver Metastases. Endocrinol Metab Clin North Am 2018;47:627-43. [PMID: 30098720 DOI: 10.1016/j.ecl.2018.04.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
123 Cloyd JM, Wiseman JT, Pawlik TM. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol 2020;11:590-600. [PMID: 32655938 DOI: 10.21037/jgo.2019.11.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
124 Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World J Gastroenterol 2016; 22(11): 3105-3116 [PMID: 27003988 DOI: 10.3748/wjg.v22.i11.3105] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
125 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17:17-22. [PMID: 24636662 DOI: 10.1111/hpb.12225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
126 Tang X, Chen Y, Guo L, Zhang J, Wang C. Prognostic Significance of Metastatic Lymph Node Number, Ratio and Station in Gastric Neuroendocrine Carcinoma. J Gastrointest Surg 2015;19:234-41. [DOI: 10.1007/s11605-014-2691-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
127 Hernandez Vargas S, Kossatz S, Voss J, Ghosh SC, Tran Cao HS, Simien J, Reiner T, Dhingra S, Fisher WE, Azhdarinia A. Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Clin Cancer Res 2019;25:4332-42. [PMID: 31015345 DOI: 10.1158/1078-0432.CCR-18-3312] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
128 Dogeas E, Karagkounis G, Heaphy CM, Hirose K, Pawlik TM, Wolfgang CL, Meeker A, Hruban RH, Cameron JL, Choti MA. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. J Am Coll Surg 2014;218:628-35. [PMID: 24655849 DOI: 10.1016/j.jamcollsurg.2014.01.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
129 Wakabayashi T, Hibi T, Yoneda G, Iwao Y, Sawada Y, Hoshino H, Uemura S, Ban D, Kudo A, Takemura Y, Mishima K, Shinoda M, Itano O, Otsubo T, Endo I, Kitagawa Y, Tanabe M, Egawa H, Yamamoto M. Predictive model for survival after liver resection for noncolorectal liver metastases in the modern era: a Japanese multicenter analysis. J Hepatobiliary Pancreat Sci 2019;26:441-8. [PMID: 31271511 DOI: 10.1002/jhbp.654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Sham JG, Ejaz A, Gage MM, Bagante F, Reames BN, Maithel S, Poultsides GA, Bauer TW, Fields RC, Weiss MJ, Marques HP, Aldrighetti L, Pawlik TM, He J. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. J Gastrointest Surg. 2019;23:484-491. [PMID: 29980977 DOI: 10.1007/s11605-018-3862-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
131 Sartori S, Bianchi L, Di Vece F, Tombesi P. Liver-directed therapies for liver metastases from neuroendocrine neoplasms: Can laser ablation play any role? World J Gastroenterol 2020; 26(23): 3118-3125 [PMID: 32684730 DOI: 10.3748/wjg.v26.i23.3118] [Reference Citation Analysis]
132 Tan QQ, Wang X, Yang L, Chen YH, Tan CL, Zhu XM, Ke NW, Liu XB. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors. Medicine (Baltimore) 2020;99:e20324. [PMID: 32541455 DOI: 10.1097/MD.0000000000020324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 He CB, Zhang Y, Cai ZY, Lin XJ. The impact of surgery in metastatic pancreatic neuroendocrine tumors: a competing risk analysis. Endocr Connect 2019;8:239-51. [PMID: 30726772 DOI: 10.1530/EC-18-0485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
134 Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol 2012;2012:973946. [PMID: 23227348 DOI: 10.1155/2012/973946] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
135 Shimura M, Mizuma M, Takadate T, Katoh Y, Suzuki T, Iseki M, Hata T, Aoki S, Suzuki Y, Sakata N, Ohtsuka H, Hayashi H, Morikawa T, Nakagawa K, Motoi F, Naitoh T, Igarashi K, Sasano H, Unno M. A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis. Oncotarget 2018;9:24291-303. [PMID: 29849941 DOI: 10.18632/oncotarget.25110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
136 Dahdaleh FS, Calva-Cerqueira D, Carr JC, Liao J, Mezhir JJ, O'Dorisio TM, Howe JR. Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution. Ann Surg Oncol 2012;19:966-72. [PMID: 21845496 DOI: 10.1245/s10434-011-1997-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
137 Chen HY, Zhang XY, Deng XY, Ge YL, Tang YQ, Cui H, Yang B, Pan Y, Shi D, Yu RS. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol 2020;215:390-7. [PMID: 32432906 DOI: 10.2214/AJR.19.21921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
138 Orgera G, Krokidis M, Cappucci M, Gourtsoyianni S, Tipaldi MA, Hatzidakis A, Rebonato A, Rossi M. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs). Cardiovasc Intervent Radiol. 2015;38:13-24. [PMID: 25366087 DOI: 10.1007/s00270-014-1005-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
139 Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, Clark Gamblin T, Celinski SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Arrese D, Ferrero A, Schulick RD, Choti MA, Geschwind JF, Strub J, Bauer TW, Adams RB, Aldrighetti L, Mentha G, Capussotti L, Pawlik TM. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011;18:3657-65. [PMID: 21681380 DOI: 10.1245/s10434-011-1832-y] [Cited by in Crossref: 113] [Cited by in F6Publishing: 98] [Article Influence: 11.3] [Reference Citation Analysis]
140 Sherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. Surgery 2013;154:1206-13; discussion 1214. [PMID: 24238043 DOI: 10.1016/j.surg.2013.04.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
141 Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015;121:1172-86. [PMID: 25274401 DOI: 10.1002/cncr.28760] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 11.9] [Reference Citation Analysis]
142 Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg 2013;216:123-34. [PMID: 23063263 DOI: 10.1016/j.jamcollsurg.2012.08.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
143 Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32-45. [PMID: 27236421 DOI: 10.1016/j.ctrv.2016.05.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
144 Scoville SD, Xourafas D, Ejaz AM, Tsung A, Pawlik T, Cloyd JM. Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. World J Gastrointest Surg 2020; 12(4): 159-170 [PMID: 32426095 DOI: 10.4240/wjgs.v12.i4.159] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
145 Fisher AT, Titan AL, Foster DS, Worth PJ, Poultsides GA, Visser BC, Dua MM, Norton JA. Management of Ileal Neuroendocrine Tumors with Liver Metastases. J Gastrointest Surg 2020;24:1530-9. [DOI: 10.1007/s11605-019-04309-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
146 Sartori S, Tombesi P, Di Vece F, Bianchi L, Ambrosio R. Percutaneous Laser Ablation of Liver Metastases from Neuroendocrine Neoplasm. A Retrospective Study for Safety and Effectiveness. Cardiovasc Intervent Radiol. 2019;42:1571-1578. [PMID: 31410534 DOI: 10.1007/s00270-019-02308-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Karabulut K, Akyildiz HY, Lance C, Aucejo F, McLennan G, Agcaoglu O, Siperstein A, Berber E. Multimodality treatment of neuroendocrine liver metastases. Surgery 2011;150:316-25. [PMID: 21801968 DOI: 10.1016/j.surg.2011.05.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
148 Graff-Baker AN, Sauer DA, Pommier SJ, Pommier RF. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. Surgery. 2014;156:1369-1376; discussion 1376-1377. [PMID: 25456912 DOI: 10.1016/j.surg.2014.08.009] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 8.6] [Reference Citation Analysis]
149 Tsilimigras DI, Squires MH, Cloyd JM, Pawlik TM. Treatment strategies for neuroendocrine liver metastases: an update. Expert Opinion on Orphan Drugs 2019;7:327-35. [DOI: 10.1080/21678707.2019.1651639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16:1696-1704. [PMID: 22644446 DOI: 10.1007/s11605-012-1912-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
151 Manguso N, Nissen N, Hendifar A, Harit A, Mirocha J, Friedman M, Lipshutz HG, Amersi F. Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases. J Surg Oncol 2019;120:926-31. [PMID: 31396982 DOI: 10.1002/jso.25657] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
152 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Reference Citation Analysis]
153 Spolverato G, Bagante F, Tsilimigras DI, Pawlik TM. Liver transplantation in patients with liver metastases from neuroendocrine tumors. Minerva Chir 2019;74:399-406. [PMID: 31280548 DOI: 10.23736/S0026-4733.19.08119-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
154 Kim KW, Krajewski KM, Nishino M, Jagannathan JP, Shinagare AB, Tirumani SH, Ramaiya NH. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR Am J Roentgenol 2013;201:811-24. [PMID: 24059370 DOI: 10.2214/AJR.12.10240] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
155 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg 2015;19:2273-82. [DOI: 10.1007/s11605-015-2931-z] [Reference Citation Analysis]
156 Valentino J, Evers BM. Recent advances in the diagnosis and treatment of gastrointestinal carcinoids. Adv Surg 2011;45:285-300. [PMID: 21954695 DOI: 10.1016/j.yasu.2011.03.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
157 Dogeas E, Chong CCN, Weiss MJ, Ahuja N, Choti MA. Can echogenic appearance of neuroendocrine liver metastases on intraoperative ultrasonography predict tumor biology and prognosis? HPB (Oxford) 2018;20:237-43. [PMID: 29103839 DOI: 10.1016/j.hpb.2017.08.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
158 Gangi A, Anaya DA. Surgical Principles in the Management of Small Bowel Neuroendocrine Tumors. Curr Treat Options Oncol 2020;21:88. [PMID: 32862334 DOI: 10.1007/s11864-020-00784-2] [Reference Citation Analysis]
159 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg 2015;19:2273-82. [DOI: 10.1007/s11605-015-2931-z] [Reference Citation Analysis]
160 Valadares LJ, Costa Junior W, Ribeiro HS, Diniz AL, Coimbra FJ, Herman P. Resection of liver metastasis from neuroendocrine tumors: evaluation of results and prognostic factors. Rev Col Bras Cir. 2015;42:25-31. [PMID: 25992697 DOI: 10.1590/0100-69912015001006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
161 Perrodin SF, Renzulli MM, Maurer MH, Kim-Fuchs C, Candinas D, Beldi G, Lachenmayer A. CAN MICROWAVE ABLATION BE AN ALTERNATIVE TO RESECTION FOR THE TREATMENT OF NEUROENDOCRINE LIVER METASTASES? Endocr Pract 2020;26:378-87. [PMID: 31859556 DOI: 10.4158/EP-2019-0394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
162 Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715-731. [PMID: 28609357 DOI: 10.1097/mpa.0000000000000846] [Cited by in Crossref: 127] [Cited by in F6Publishing: 58] [Article Influence: 42.3] [Reference Citation Analysis]
163 Lehrman ED, Fidelman N. Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy. Semin Intervent Radiol 2020;37:499-507. [PMID: 33328706 DOI: 10.1055/s-0040-1720951] [Reference Citation Analysis]
164 Chua TC, Crowe PJ, Morris DL. Trends in surgical oncology research in Australia during the period 1998-2009--a bibliometric review. J Surg Oncol 2011;104:216-9. [PMID: 21472735 DOI: 10.1002/jso.21942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
165 Wulfert S, Kratochwil C, Choyke PL, Afshar-Oromieh A, Mier W, Kauczor HU, Schenk JP, Haberkorn U, Giesel FL. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Mol Imaging Biol 2014;16:586-94. [PMID: 24526358 DOI: 10.1007/s11307-014-0722-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
166 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Reference Citation Analysis]
167 Linecker M, Kambakamba P, Raptis DA, Malagó M, Ratti F, Aldrighetti L, Robles-Campos R, Lehwald-Tywuschik N, Knoefel WT, Balci D, Ardiles V, De Santibañes E, Truant S, Pruvot FR, Stavrou GA, Oldhafer KJ, Voskanyan S, Mahadevappa B, Kozyrin I, Low JK, Ferrri V, Vicente E, Prachalias A, Pizanias M, Clift AK, Petrowsky H, Clavien PA, Frilling A. ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry. HPB (Oxford) 2020;22:537-44. [PMID: 31540885 DOI: 10.1016/j.hpb.2019.08.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
168 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H, Xu Y, Chi T, Zhao H, Wang W, Cui Q, Zhong S, Huang J, Mao Y. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia. Medicine (Baltimore) 2015;94:e388. [PMID: 25590842 DOI: 10.1097/MD.0000000000000388] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
170 Sherman SK, Maxwell JE, Carr JC, Wang D, Bellizzi AM, Sue O'Dorisio M, O'Dorisio TM, Howe JR. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clin Exp Metastasis 2014;31:935-44. [PMID: 25241033 DOI: 10.1007/s10585-014-9681-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
171 Maeda Y, Shinohara T, Katayama T, Futakawa N, Hamada T. Hepatectomy for liver metastases in non-colorectal, non-neuroendocrine cancer patients. The survival benefit in primary unresectable cases. Int J Surg 2015;22:136-42. [PMID: 26277530 DOI: 10.1016/j.ijsu.2015.07.716] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
172 Sher LS, Levi DM, Wecsler JS, Lo M, Petrovic LM, Groshen S, Ji L, Uso TD, Tector AJ, Hamilton AS, Marsh JW, Schwartz ME. Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables. J Surg Oncol 2015;112:125-32. [PMID: 26171686 DOI: 10.1002/jso.23973] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
173 Bösch F, Ilhan H, Pfahler V, Thomas M, Knösel T, Eibl V, Pratschke S, Bartenstein P, Seidensticker M, Auernhammer CJ, Spitzweg C, Guba MO, Werner J, Angele MK. Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. Hepatobiliary Surg Nutr 2020;9:312-21. [PMID: 32509817 DOI: 10.21037/hbsn.2019.07.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
174 Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142. [PMID: 30007406 DOI: 10.1186/s12957-018-1446-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
175 Dong DH, Zhang XF, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Dillhoff M, Maithel SK, Pawlik TM. Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. HPB (Oxford) 2020;22:215-23. [PMID: 31235429 DOI: 10.1016/j.hpb.2019.05.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
176 Sadowski SM, Millo C, Neychev V, Aufforth R, Keutgen X, Glanville J, Alimchandani M, Nilubol N, Herscovitch P, Quezado M, Kebebew E. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2015;22 Suppl 3:S676-82. [PMID: 26350374 DOI: 10.1245/s10434-015-4857-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
177 Clift AK, Frilling A. Management of patients with hepatic metastases from neuroendocrine tumors. Ann Saudi Med. 2014;34:279-290. [PMID: 25811199 DOI: 10.5144/0256-4947.2014.279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
178 Keck KJ, Maxwell JE, Menda Y, Bellizzi A, Dillon J, O'Dorisio TM, Howe JR. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors. Surgery 2017;161:272-9. [PMID: 27863780 DOI: 10.1016/j.surg.2016.05.055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
179 Bartlett EK, Roses RE, Gupta M, Shah PK, Shah KK, Zaheer S, Wachtel H, Kelz RR, Karakousis GC, Fraker DL. Surgery for metastatic neuroendocrine tumors with occult primaries. J Surg Res. 2013;184:221-227. [PMID: 23643298 DOI: 10.1016/j.jss.2013.04.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
180 Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165:166-175. [PMID: 30343949 DOI: 10.1016/j.surg.2018.04.070] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
181 Kelly P, Ma Z, Baidas S, Moroose R, Shah N, Dagan R, Mamounas E, Rineer J. Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy. Int J Breast Cancer 2017;2017:1367159. [PMID: 29147583 DOI: 10.1155/2017/1367159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
182 Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol 2012;21:e131-41. [PMID: 22658833 DOI: 10.1016/j.suronc.2012.05.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
183 Wong KP, Tsang JS, Lang BH. Role of surgery in pancreatic neuroendocrine tumor. Gland Surg 2018;7:36-41. [PMID: 29629318 DOI: 10.21037/gs.2017.12.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
184 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 2015;12:481-9. [PMID: 25985939 DOI: 10.1038/nrclinonc.2015.78] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
185 Castillo JG, Silvay G, Solís J. Current concepts in diagnosis and perioperative management of carcinoid heart disease. Semin Cardiothorac Vasc Anesth 2013;17:212-23. [PMID: 23171718 DOI: 10.1177/1089253212465475] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
186 Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am 2019;99:793-814. [PMID: 31255207 DOI: 10.1016/j.suc.2019.04.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
187 Flaum N, Valle JW, Mansoor W, Mcnamara MG. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Future Oncology 2016;12:2561-78. [DOI: 10.2217/fon.16.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
188 Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR, Kebebew E. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Semin Oncol 2018;45:232-5. [PMID: 30318110 DOI: 10.1053/j.seminoncol.2018.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
189 Xiang J, Zhang X, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis. Ann Surg Oncol 2020;27:3717-26. [DOI: 10.1245/s10434-020-08620-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
190 Haugvik SP, Labori KJ, Edwin B, Mathisen Ø, Gladhaug IP. Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. ScientificWorldJournal. 2012;2012:357475. [PMID: 23304085 DOI: 10.1100/2012/357475] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
191 Yu X, Gu J, Wu H, Fu D, Li J, Jin C. Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Oncol. 2018;2018:6273947. [PMID: 30538745 DOI: 10.1155/2018/6273947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
192 Labgaa I, Slankamenac K, Schadde E, Jibara G, Alshebeeb K, Mentha G, Clavien P, Schwartz M. Liver resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: A multicentric study. The American Journal of Surgery 2018;215:125-30. [DOI: 10.1016/j.amjsurg.2017.09.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
193 Niederle B, Selberherr A, Niederle MB. How to Manage Small Intestine (Jejunal and Ileal) Neuroendocrine Neoplasms Presenting with Liver Metastases? Curr Oncol Rep 2021;23:85. [PMID: 34018081 DOI: 10.1007/s11912-021-01074-2] [Reference Citation Analysis]
194 Megdanova-Chipeva VG, Lamarca A, Backen A, McNamara MG, Barriuso J, Sergieva S, Gocheva L, Mansoor W, Manoharan P, Valle JW. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers (Basel) 2020;12:E1988. [PMID: 32708210 DOI: 10.3390/cancers12071988] [Reference Citation Analysis]
195 Polcz M, Schlegel C, Edwards GC, Wang F, Tan M, Kiernan C, Solórzano CC, Idrees K, Parikh A, Bailey CE. Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors. Ann Surg Oncol 2020;27:2795-803. [PMID: 32430752 DOI: 10.1245/s10434-020-08602-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
196 Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018;59:66-74. [PMID: 29025982 DOI: 10.2967/jnumed.117.202275] [Cited by in Crossref: 99] [Cited by in F6Publishing: 81] [Article Influence: 24.8] [Reference Citation Analysis]
197 Cusati D, Zhang L, Harmsen WS, Hu A, Farnell MB, Nagorney DM, Donohue JH, Que FG, Reid-lombardo KM, Kendrick ML. Metastatic Nonfunctioning Pancreatic Neuroendocrine Carcinoma to Liver: Surgical Treatment and Outcomes. Journal of the American College of Surgeons 2012;215:117-24. [DOI: 10.1016/j.jamcollsurg.2012.05.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
198 Tsutsumi K, Ohtsuka T, Fujino M, Nakashima H, Aishima S, Ueda J, Takahata S, Nakamura M, Oda Y, Tanaka M. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepatobiliary Pancreat Sci 2014;21:418-25. [DOI: 10.1002/jhbp.47] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
199 Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, Whitt J, Carter AM, Markert JM, Bibb JA, Chen H, Zhou L, Jaskula-Sztul R, Liu XM. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Ther 2021;28:799-812. [PMID: 32684623 DOI: 10.1038/s41417-020-0196-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
200 Zhang X, Beal EW, Chakedis J, Lv Y, Bagante F, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Weiss M, Pawlik TM. Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment. J Gastrointest Surg 2017;21:1821-30. [DOI: 10.1007/s11605-017-3490-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
201 Page AJ, Weiss MJ, Pawlik TM. Surgical management of noncolorectal cancer liver metastases: Noncolorectal Liver Metatases. Cancer 2014;120:3111-21. [DOI: 10.1002/cncr.28743] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
202 Wang M, Zhou J, Zhang L, Zhao Y, Zhang N, Wang L, Zhu W, He X, Zhu H, Xu W, Pan Q, Mao A, Li Q. Surgical treatment of ovarian cancer liver metastasis.Hepatobiliary Surg Nutr. 2019;8:129-137. [PMID: 31098360 DOI: 10.21037/hbsn.2018.12.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
203 Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. J Thorac Oncol 2017;12:425-36. [PMID: 27890494 DOI: 10.1016/j.jtho.2016.11.2222] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 17.4] [Reference Citation Analysis]
204 Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49:1-33. [PMID: 31856076 DOI: 10.1097/mpa.0000000000001454] [Cited by in Crossref: 56] [Cited by in F6Publishing: 23] [Article Influence: 56.0] [Reference Citation Analysis]
205 Triantafyllidis I, Gayet B, Tsiakyroudi S, Tabchouri N, Beaussier M, Bennamoun M, Sarran A, Lefevre M, Louvet C, Fuks D. Perioperative and long-term outcomes of laparoscopic liver resections for non-colorectal liver metastases. Surg Endosc 2020;34:3833-44. [PMID: 31586246 DOI: 10.1007/s00464-019-07148-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Xiang JX, Zhang XF, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome. J Surg Oncol 2018;118:1096-104. [PMID: 30261105 DOI: 10.1002/jso.25246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
207 Fan KY, Wild AT, Halappa VG, Kumar R, Ellsworth S, Ziegler M, Garg T, Rosati LM, Su Z, Hacker-Prietz A, Pawlik TM, Cosgrove DP, Hong KK, Kamel IR, Geschwind JF, Herman JM. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin Trials 2016;50:143-9. [PMID: 27520932 DOI: 10.1016/j.cct.2016.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
208 Spolverato G, Bagante F, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Weiss M, Pawlik TM. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis. J Surg Oncol 2017;116:298-306. [DOI: 10.1002/jso.24670] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
209 Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159:320-333. [PMID: 26454679 DOI: 10.1016/j.surg.2015.05.040] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 14.3] [Reference Citation Analysis]
210 Maxwell JE, Sherman SK, Howe JR. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2016;22:5022-9. [PMID: 27742788 DOI: 10.1158/1078-0432.CCR-16-0435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
211 Titan AL, Norton JA, Fisher AT, Foster DS, Harris EJ, Worhunsky DJ, Worth PJ, Dua MM, Visser BC, Poultsides GA, Longaker MT, Jensen RT. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors. JAMA Netw Open 2020;3:e2024318. [PMID: 33146734 DOI: 10.1001/jamanetworkopen.2020.24318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
212 D’Haese JG, Tosolini C, Ceyhan GO, Kong B, Esposito I, Michalski CW, Kleeff J. Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol 2014; 20(38): 13893-13898 [PMID: 25320524 DOI: 10.3748/wjg.v20.i38.13893] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
213 Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, Clancy TE. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Ann Surg Oncol. 2017;24:2319-2325. [PMID: 28303430 DOI: 10.1245/s10434-017-5839-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
214 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg. 2015;19:2273-2282. [PMID: 26341823 DOI: 10.1007/s11605-015-2931-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
215 Bhutiani N, Philips P, Martin RC 2nd, Scoggins CR. Impact of surgical margin clearance for resection of secondary hepatic malignancies. J Surg Oncol. 2016;113:289-295. [PMID: 26662026 DOI: 10.1002/jso.24107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
216 Elias D, David A, Sourrouille I, Honoré C, Goéré D, Dumont F, Stoclin A, Baudin E. Neuroendocrine carcinomas: Optimal surgery of peritoneal metastases (and associated intra-abdominal metastases). Surgery 2014;155:5-12. [DOI: 10.1016/j.surg.2013.05.030] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
217 de Jong KP, Wertenbroek MW. Liver Resection Combined with Local Ablation: Where Are the Limits? Dig Surg 2011;28:127-33. [DOI: 10.1159/000323823] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
218 White BE, Mujica-Mota R, Snowsill T, Gamper EM, Srirajaskanthan R, Ramage JK. Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. Rev Endocr Metab Disord 2021;22:647-63. [PMID: 33155118 DOI: 10.1007/s11154-020-09608-y] [Reference Citation Analysis]